Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleHot Topics

Will GRPR Compete with PSMA as a Target in Prostate Cancer?

Andrei Iagaru
Journal of Nuclear Medicine December 2017, 58 (12) 1883-1884; DOI: https://doi.org/10.2967/jnumed.117.198192
Andrei Iagaru
Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, Stanford, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Imaging of prostate cancer (PCa) plays an important role in guiding biopsy at initial diagnosis, in accurately evaluating the extent of disease, in assessing sites of recurrent disease, and in monitoring response to treatment. A variety of PET radiopharmaceuticals for PCa are in clinical trials or available commercially.

Prostate-specific membrane antigen (PSMA) is a transmembrane protein that is highly overexpressed on almost all PCas (1). Only 5%–10% of primary PCa lesions have been shown to be PSMA-negative (2), making this class of radiopharmaceutical suitable for diagnosis of primary PCa and for initial staging (3,4). Use for noninvasive tumor grading has also been reported (3). High accuracy has been reported for use in detecting biochemical recurrence, even at very low prostate-specific antigen levels (5,6). However, these promising agents do not detect all recurrences (5,7), and other types of cancer also express PSMA (8,9). False-positive findings have also been reported using PSMA agents (10–12). Given the widespread adoption of PSMA radiopharmaceuticals and their excellent performance at all stages of PCa, is there a need or a role for another class of PET radiopharmaceutical targeting other biologic processes in PCa?

Gastrin-releasing peptide receptor (GRPR) is a G-protein–coupled receptor overexpressed in many types of cancer, such as PCa, breast cancer, and small cell lung cancer (13). It belongs to the bombesin receptor family. Bombesin is a 14-mer peptide (Pyr-Gln-Arg-Leu-Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2) that binds with high affinity to the GRPR (14). Clinically translated GRPR antagonist PET radiopharmaceuticals include 68Ga-RM2, 68Ga-SB3, 68Ga-NeoBOMB1, 18F-BAY-864367, and 64Cu-CB-TE2A-AR06. They have a stable biodistribution in healthy volunteers (15) and mean effective doses comparable to those of other radiopharmaceuticals (16,17). Data are encouraging regarding their potential for the initial diagnosis of PCa (15–19), for the assessment of biochemical recurrence (15,16,18–23), and for the theranostic approach (24). The lack of salivary or lacrimal gland uptake and the low hepatobiliary clearance give them an advantage. The high pancreatic uptake may be of concern to some; however, although initial uptake is high, it decreases rapidly whereas tumor radioactivity is retained longer (24). A comparison of 68Ga-RM2 PET scans before and after treatment is shown in Figure 1, and comparisons of paired 68Ga-PSMA-11 and 68Ga-RM2 scans are shown in Figure 2.

FIGURE 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1.

72-y-old man with history of Gleason 3 + 4 PCa treated with radiation and hormonal therapy, presenting with prostate-specific antigen level of 3.7 ng/mL. Maximum-intensity-projection 68Ga-RM2 PET images before (A) and after (B) radiation treatment demonstrate resolution of prostate bed uptake (arrow).

FIGURE 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 2.

Maximum-intensity-projection PET images from 68Ga-PSMA-11 and 68Ga-RM2 PET scan pairs show no uptake on 68Ga-PSMA-11 PET and focal uptake (arrow) in retroperitoneal lymph nodes on 68Ga-RM2 PET (A), focal uptake (arrow) in retroperitoneal lymph nodes on 68Ga-PSMA-11 PET and no uptake on 68Ga-RM2 PET (B), and focal uptake (arrows) in seminal vesicle on both 68Ga-PSMA-11 PET and 68Ga-RM2 PET (C).

Although the overexpression of PSMA is ubiquitous in PCa, it is not universal and there will be lesions not detected by PSMA-targeted imaging in different risk classes or stages of disease. The influence of GRPR expression on cancer grade and stage is not clear. Nagasaki et al. (25) found that GRPR expression was positively correlated with Gleason score, but another study found that GRPR expression was inversely correlated with Gleason score, preoperative prostate-specific antigen concentration, and tumor size (26). Therefore, the indication (i.e., low- vs. intermediate- vs high-risk, and early vs. late stage of disease) for the use of PSMA- vs. GRPR-targeted imaging or both is an active focus of research.

Another unsettled question is whether the uptake is specific for (prostate) cancer. High uptake was reported in primary PCa lesions and metastases (16,18,23), but benign prostate hypertrophy resulted in false-positive findings in some cases (16). This may be avoided by the development of appropriate metrics of image interpretation. In our experience with 68Ga-RM2, all 7 biopsied lesions (prostate, lymph nodes, liver, and lung nodule) were confirmed PCa (22). As GRPR-targeting radiopharmaceuticals are evaluated in more patients, it is likely that more reports of non–cancer-specific uptake will emerge, as with any new class of radiopharmaceutical.

There are limitations to the data supporting the use of GRPR-targeting PET peptides, including small clinical studies, limited gold standards, and limited outcome data based on their use. Larger studies are needed to confirm preliminary results. However, given the complexity of the biologic processes identified in PCa, it is unlikely that any one group of imaging agents will provide all the answers needed to offer the best care for these patients. Therefore, the continued development and introduction to clinical use of GRPR-targeting PET radiopharmaceuticals will continue, if not as direct competitors of PSMA-targeting tracers, then as complementary diagnostic and therapeutic approaches. The sum is better than the parts after all.

DISCLOSURE

No potential conflict of interest relevant to this article was reported.

Footnotes

  • Published online Sep. 28, 2017.

  • © 2017 by the Society of Nuclear Medicine and Molecular Imaging.

REFERENCES

  1. 1.↵
    1. Silver DA,
    2. Pellicer I,
    3. Fair WR,
    4. Heston WD,
    5. Cordon-Cardo C
    . Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3:81–85.
    OpenUrlAbstract
  2. 2.↵
    1. Budäus L,
    2. Leyh-Bannurah SR,
    3. Salomon G,
    4. et al
    . Initial experience of 68Ga-PSMA PET/CT imaging in high-risk prostate cancer patients prior to radical prostatectomy. Eur Urol. 2016;69:393–396.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Koerber SA,
    2. Utzinger MT,
    3. Kratochwil C,
    4. et al
    . 68Ga-PSMA11-PET/CT in newly diagnosed carcinoma of the prostate: correlation of intraprostatic PSMA uptake with several clinical parameters. J Nucl Med. June 15, 2017 [Epub ahead of print].
  4. 4.↵
    1. Fendler WP,
    2. Schmidt DF,
    3. Wenter V,
    4. et al
    . 68Ga-PSMA PET/CT detects the location and extent of primary prostate cancer. J Nucl Med. 2016;57:1720–1725.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Eiber M,
    2. Maurer T,
    3. Souvatzoglou M,
    4. et al
    . Evaluation of hybrid 68Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015;56:668–674.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Afshar-Oromieh A,
    2. Avtzi E,
    3. Giesel FL,
    4. et al
    . The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:197–209.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Rowe SP,
    2. Gage KL,
    3. Faraj SF,
    4. et al
    . 18F-DCFBC PET/CT for PSMA-based detection and characterization of primary prostate cancer. J Nucl Med. 2015;56:1003–1010.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Sathekge M,
    2. Lengana T,
    3. Modiselle M,
    4. et al
    . 68Ga-PSMA-HBED-CC PET imaging in breast carcinoma patients. Eur J Nucl Med Mol Imaging. 2017;44:689–694.
    OpenUrl
  9. 9.↵
    1. Rhee H,
    2. Blazak J,
    3. Tham CM,
    4. et al
    . Pilot study: use of gallium-68 PSMA PET for detection of metastatic lesions in patients with renal tumour. EJNMMI Res. 2016;6:76.
    OpenUrl
  10. 10.↵
    1. Hermann RM,
    2. Djannatian M,
    3. Czech N,
    4. Nitsche M
    . Prostate-specific membrane antigen PET/CT: false-positive results due to sarcoidosis? Case Rep Oncol. 2016;9:457–463.
    OpenUrl
  11. 11.
    1. Sasikumar A,
    2. Joy A,
    3. Nanabala R,
    4. Pillai MR
    , T AH. 68Ga-PSMA PET/CT false-positive tracer uptake in Paget disease. Clin Nucl Med. 2016;41:e454–e455.
    OpenUrl
  12. 12.↵
    1. Noto B,
    2. Vrachimis A,
    3. Schafers M,
    4. Stegger L,
    5. Rahbar K
    . Subacute stroke mimicking cerebral metastasis in 68Ga-PSMA-HBED-CC PET/CT. Clin Nucl Med. 2016;41:e449–e451.
    OpenUrl
  13. 13.↵
    1. Mansi R,
    2. Fleischmann A,
    3. Macke HR,
    4. Reubi JC
    . Targeting GRPR in urological cancers: from basic research to clinical application. Nat Rev Urol. 2013;10:235–244.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Jensen RT,
    2. Battey JF,
    3. Spindel ER,
    4. Benya RV
    . International Union of Pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states. Pharmacol Rev. 2008;60:1–42.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Roivainen A,
    2. Kahkonen E,
    3. Luoto P,
    4. et al
    . Plasma pharmacokinetics, whole-body distribution, metabolism, and radiation dosimetry of 68Ga bombesin antagonist BAY 86-7548 in healthy men. J Nucl Med. 2013;54:867–872.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Kähkönen E,
    2. Jambor I,
    3. Kemppainen J,
    4. et al
    . In vivo imaging of prostate cancer using [68Ga]-labeled bombesin analog BAY86-7548. Clin Cancer Res. 2013;19:5434–5443.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. Wieser G,
    2. Mansi R,
    3. Grosu AL,
    4. et al
    . Positron emission tomography (PET) imaging of prostate cancer with a gastrin releasing peptide receptor antagonist: from mice to men. Theranostics. 2014;4:412–419.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Nock BA,
    2. Kaloudi A,
    3. Lymperis E,
    4. et al
    . Theranostic perspectives in prostate cancer with the gastrin-releasing peptide receptor antagonist NeoBOMB1: preclinical and first clinical results. J Nucl Med. 2017;58:75–80.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Sah BR,
    2. Burger IA,
    3. Schibli R,
    4. et al
    . Dosimetry and first clinical evaluation of the new 18F-radiolabeled bombesin analogue BAY 864367 in patients with prostate cancer. J Nucl Med. 2015;56:372–378.
    OpenUrlAbstract/FREE Full Text
  20. 20.
    1. Minamimoto R,
    2. Hancock S,
    3. Schneider B,
    4. et al
    . Pilot comparison of 68Ga-RM2 PET and 68Ga-PSMA-11 PET in patients with biochemically recurrent prostate cancer. J Nucl Med. 2016;57:557–562.
    OpenUrlAbstract/FREE Full Text
  21. 21.
    1. Wieser G,
    2. Popp I,
    3. Christian Rischke H,
    4. et al
    . Diagnosis of recurrent prostate cancer with PET/CT imaging using the gastrin-releasing peptide receptor antagonist 68Ga-RM2: preliminary results in patients with negative or inconclusive [18F]fluoroethylcholine-PET/CT. Eur J Nucl Med Mol Imaging. 2017;44:1463–1472.
    OpenUrl
  22. 22.↵
    1. Harrison C,
    2. Sonni I,
    3. Loening A,
    4. Vasanawala S,
    5. Iagaru A
    . Detection of recurrent prostate cancer using 68Ga-RM2 PET/MRI in patients with negative conventional imaging [abstract]. J Nucl Med. 2017;58(suppl 1):711.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Maina T,
    2. Bergsma H,
    3. Kulkarni HR,
    4. et al
    . Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [68Ga]SB3 and PET/CT. Eur J Nucl Med Mol Imaging. 2016;43:964–973.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Dalm SU,
    2. Bakker IL,
    3. de Blois E,
    4. et al
    . 68Ga/177Lu-NeoBOMB1, a novel radiolabeled GRPR antagonist for theranostic use in oncology. J Nucl Med. 2017;58:293–299.
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    1. Nagasaki S,
    2. Nakamura Y,
    3. Maekawa T,
    4. et al
    . Immunohistochemical analysis of gastrin-releasing peptide receptor (GRPR) and possible regulation by estrogen receptor βcx in human prostate carcinoma. Neoplasma. 2012;59:224–232.
    OpenUrlPubMed
  26. 26.↵
    1. Beer M,
    2. Montani M,
    3. Gerhardt J,
    4. et al
    . Profiling gastrin-releasing peptide receptor in prostate tissues: clinical implications and molecular correlates. Prostate. 2012;72:318–325.
    OpenUrlCrossRefPubMed
  • Received for publication August 28, 2017.
  • Accepted for publication September 13, 2017.
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 58 (12)
Journal of Nuclear Medicine
Vol. 58, Issue 12
December 1, 2017
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Will GRPR Compete with PSMA as a Target in Prostate Cancer?
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Will GRPR Compete with PSMA as a Target in Prostate Cancer?
Andrei Iagaru
Journal of Nuclear Medicine Dec 2017, 58 (12) 1883-1884; DOI: 10.2967/jnumed.117.198192

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Will GRPR Compete with PSMA as a Target in Prostate Cancer?
Andrei Iagaru
Journal of Nuclear Medicine Dec 2017, 58 (12) 1883-1884; DOI: 10.2967/jnumed.117.198192
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • Utility of 64Cu-Sarcophagine-Bombesin PET/CT in Men with Biochemically Recurrent Prostate Cancer and Negative or Equivocal Findings on 68Ga-PSMA-11 PET/CT
  • Exploitation of CD133 for the Targeted Imaging of Lethal Prostate Cancer
  • Google Scholar

More in this TOC Section

  • RECIP 1.0: A Roadmap for Clinical Implementation
  • Diagnostic Radiopharmaceutical Trial Design: Is It Time to Change Nomenclature?
  • From Stabilization to Depletion: Molecular Imaging to Measure Therapeutic Response in ATTR-CA
Show more Hot Topics

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire